Edwards Lifesciences May Continue To Rise After Positive Clinical Trial Data
- Monday, June 28, 2021, 7:15
- Market
- Add a comment
The stock price of Edward Lifesciences, a company specializing in artificial heart valves and hemodynamic monitoring, has seen a rise of 10% in the last twenty-one trading days. This can be attributed to the positive outcome from a clinical trial for Evoque tricuspid and Pascal system for patients..
About the Author
admin123 has written 23412 stories on this site.
